Christmas brings the spirit of giving, and so Telethon presents a festive concert in support of the Cyprus Institute of ...
The FDA approved the intrathecal gene therapy onasemnogene abeparvovec (Itvisma) to treat spinal muscular atrophy (SMA) in ...
The FDA has approved Itvisma (onasemnogene abeparvovec-brve) to treat children two years and older, teens, and adults living with spinal muscular atrophy (SMA). It is indicated for patients with a ...
From riding a camel in the Sahara dessert to paragliding in the Swiss Alps to trekking through the Amazon rainforest, Cory ...
Itvisma contains the active ingredient in Zolgensma approved in 2019 for children younger than 2 years but is reformulated for intrathecal administration across age groups.
The FDA approved an intrathecal form of Novartis’ spinal muscular atrophy gene therapy Zolgensma on Monday, broadening access ...
Novartis is pricing Itvisma at a wholesale acquisition cost of $2.59 million, a company spokesperson told Fierce Pharma. At ...
The U.S. Food and Drug Administration has approved Novartis' gene therapy for patients with a rare muscle disorder, the drugmaker said on Monday.
The new intrathecal formulation means the one-shot gene therapy is now available to all SMA patients, regardless of their age, and could free them from having to take regular, lifelong SMA treatments ...
Tears gathered in Jeremy Bray’s eyes as he absorbed the news that his pleas for Manitoba’s government to cover his ...
The only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA).
San Francisco 49ers legend Jerry Rice broke down what current wide receivers should do to correct a major issue with current play.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback